TECNOTREE
8.5.2024 11:45:27 CEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced its partnership with people+ai, an initiative of the non-profit EkStep Foundation, on joining the Open Cloud Compute (OCC) project.
OCC comprises of an interconnected network of micro data centres, and based on this model India requires approximately 10,000 micro data centres to bolster its compute power infrastructure. The network would bring compute capabilities closer to the end users, enabling faster processing, lower latency, and stronger data sovereignty. Tecnotree is partnering with the OCC initiative for shaping the future of AI in India, by implementing an API abstraction layer aligned with telecom standards. The collaboration aims to build a one-stop shop for AI, Cloud, and 5G services, offering a comprehensive solution to meet evolving industry needs.
The partnership aims to enhance India’s compute ecosystem by creating a network of providers offering accessible and customized compute resources. The platform shares a collective vision of bringing ecosystems together across the world, for the future common standards and capabilities for AI, Cloud Infrastructure, Sustainability, Trusted AI, Cloud Compute, and SDNs.
In addition to Tecnotree, various other technology providers are collaborating to meet increasing compute requirements. Other companies participating include industry stalwarts such as Advanced Micro Devices (AMD), Oracle, Dell Technologies, Tata Communications, IBM, and more. These partner organisations will act as providers in this compute stack or customers who have a growing need for compute.
Infosys co-founder Nandan Nilekani who co-founded EkStep Foundation held a closed-door session with representatives of more than 20 organisations on doing the groundwork to create a compute ecosystem in India, important for the creation of a single and open interface for providers and customers of computing infrastructure.
Nilekani said, “India’s approach to building technology at scale is unique. We have successfully unbundled the building blocks to create population-scale digital public infrastructure for identity, payments, and education. We see that India’s ideas for technology are being recognised globally. I believe it is now time to rebundle and make AI work to empower every individual and identify AI use cases unique to India. AI will help reduce barriers and personalise at scale.”
Prianca Ravichander, Tecnotree CMO, said, “This initiative by OCC not only enhances India’s compute ecosystem but also fosters global collaboration in establishing common standards for AI and Cloud Infrastructure. Together with other industry leaders we are dedicated to meeting the growing compute requirements. Tecnotree is partnering with OCC to make this initiative a reality.
We are dedicated to enabling the benefits of Cloud and AI through our digital products and services for telecom operators worldwide. We aim to drive forward AI and Cloud standardization globally, laying the groundwork for a more cohesive ecosystem. Together, we are laying the foundations that are not only technologically advanced but also inclusive and sustainable, propelling us towards a digitally inclusive future”.
About Tecnotree
Tecnotree has been Empowering Digitally Connected Communities to over 90+ Telecom Providers around the world, since 1978. Our leading AIML-embedded, 5G-ready digital Business Support System (BSS), with multi-cloud extensibility, has challenged traditional transformation approaches and gained acceptance across a range of emerging and established markets, currently supporting over 1 billion subscribers. Change and transformation are at the very essence of our DNA driving continuous innovation, delivering world-class experiences and monetisation capabilities to telecom operators and their customers through Tecnotree Moments, enabling essential services beyond voice and data connectivity to other digital experiences in the area of health, education, financial inclusion and beyond. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508342069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom